Can a 5-Day radiation course beat the standard for prostate cancer?
NCT ID NCT05786742
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a very short course of radiation (5 days) is as safe and effective as a longer course (2-3 weeks) for men with localized prostate cancer. All participants also receive a brachytherapy boost. The main goal is to compare side effects and quality of life over 5 years. About 205 men will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radiation therapy (ultra-hypofractionated vs. moderately hypofractionated) with HDR brachytherapy boost
- What this could lead to
- If successful, this could offer a shorter, more convenient radiation schedule for prostate cancer patients without increasing side effects.
- What could go wrong
- This is an early-phase study (phase 1-2) with a small number of participants. The ultra-short schedule may prove more toxic or less effective than standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRACHYTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHUdeQuebec
RECRUITINGQuébec, G1R 2J6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?